Notice to the Market – Grupo Biotoscana expands its partnership with Gilead Sciences in HCV in Brazil
NOTICE TO THE MARKET
BIOTOSCANA INVESTMENTS S.A. (“Company”), one of the biggest biopharmaceutical groups focused on advanced medicine in Latin American, announces to its shareholders and the market in general that it has expanded its partnership with Gilead Sciences (Nasdaq: GILD) in HCV in Brazil.
Under a previous agreement, Gilead Sciences had granted distribution rights to GBT-Grupo Biotoscana (GBT), for SOVALDI® (400 mg sofosbuvir). Under the new agreement, the parties have arranged to extend the term for SOVALDI® and include the distribution of HARVONI® (90 mg ledipasvir / 400 mg sofosbuvir). GBT maintains all its rights and obligations under prior agreement.
HARVONI® is not an approved drug in Brazil yet, where local health authorities are in the process of reviewing the health registration dossier filed by Gilead Sciences. Gilead Sciences will continue to be responsible for supplying these treatment options directly to the Brazilian Ministry of Health.
Montevideo, August 30th 2017
BIOTOSCANA INVESTMENTS S.A.
Claudio Coracini
Legal representative in Brazil
To access the material fact in PDF format, click here.
Updated on 01/02/2019 at 04:57 pm